The Avandia Debate

This publication has 30 references indexed in Scilit:

• Peroxisome proliferator–activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study
  American Heart Journal, 2007
• Coronary heart disease outcomes in patients receiving antidiabetic agents
  Pharmacoepidemiology and Drug Safety, 2007
• Rosiglitazone RECORD study: glucose control outcomes at 18 months
  Diabetic Medicine, 2007
• Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke
  Stroke, 2007
• Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
  New England Journal of Medicine, 2006
• The DREAM trial
  The Lancet, 2006
• Effect of Ramipril on the Incidence of Diabetes
  New England Journal of Medicine, 2006
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  Published by Elsevier ,2005
• Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998